Production of therapeutic in support of national emergency response to coronavirus 2019 (covid-19): in support of operation warp speed (OWS), the government is purchasing up to 1,250,000 doses of…
Ended Definitive Contract Awarded Last action
- Contract number
- W15QKN21C0014
- Awardee
-
Regeneron Pharmaceuticals Inc. UEI N3F9MH7E6HD6
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $5,565,000,000
Award facts
- Opportunity
-
- W15QKN21R0047 Solicitation number
- Posting of J&A - Production of Therapeutic (casirivimab and imdevimab) in Support of National Emergency Response to Coronavirus 2019 (COVID-19) Limited / Sole Source Justification · Posted Jan 21, 2021
- Production of Therapeutic (casirivimab and imdevimab) in Support of National Emergency Response to Coronavirus 2019 (COVID-19) Award Notice · Posted Jan 13, 2021
- Contract value 100% obligated
- $5,565,000,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Sleepy Hollow, NY 10591, USA
- National interest action
- Coronavirus COVID-19
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $2,940,000,000 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,625,000,000 |
About this award
This is a $5,565,000,000.00 Firm Fixed Price definitive contract awarded by the Joint PEO Chemical and Biological Defense, a defense agency, to Regeneron Pharmaceuticals Inc. for the production of a COVID-19 therapeutic in support of Operation Warp Speed. The contract has no set-aside and is scheduled for completion by July 31, 2022. Regeneron Pharmaceuticals Inc. is a for-profit manufacturer of goods that has expanded its services from supplying specific pharmaceutical products to large-scale production of therapeutics for national emergencies.
Description
Production of therapeutic in support of national emergency response to coronavirus 2019 (covid-19): in support of operation warp speed (OWS), the government is purchasing up to 1,250,000 doses of the emergency use authorization (EUA) therapeutic.
Quick answers
Who was awarded contract W15QKN21C0014?
W15QKN21C0014 was awarded to Regeneron Pharmaceuticals Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on January 12, 2021.
How much is contract W15QKN21C0014 worth?
The government has obligated $5,565,000,000 on W15QKN21C0014.
Which agency awarded contract W15QKN21C0014?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W15QKN21C0014, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W15QKN21C0014 competed?
The extent of competition for W15QKN21C0014 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award